Skip to main content
. 2020 Apr 20;9:7. doi: 10.1186/s40164-020-00159-1

Table 2.

Treatment-related grade ≥ 2 adverse events

Dose level 1
n = 1		 2
n = 2		 3
n = 0		 4
n = 1		 5
n = 6		 6
n = 4		 7
n = 3		 8
n = 19		 Total
N = 36

Bevacizumab

IV q2w (mg/kg)

 2.5 5 5 5 7.5 7.5 7.5 10

Cetuximab

IV weekly (mg/m2)*

 100, 75 100, 75 200, 125 200, 125 200, 125 400, 250 400, 250 400, 250

Erlotinib

PO daily (mg)

 50 50 50 100 100 100 150 150
Rash
 Grade 2 0 0 0 1 3 2 0 10 16 (44%)
 Grade 3 0 0 0 0 0 0 0 4 4 (11%)
Pruritus
 Grade 2 0 0 0 1 0 0 0 1 2 (6%)
 Grade 3 0 0 0 0 0 0 0 1 2 (6%)
Diarrhea
 Grade 2 0 0 0 0 0 0 0 3 3 (8%)
Fatigue
 Grade 2 0 0 0 0 1 0 1 0 2 (6%)
Hand-foot syndrome
 Grade 2 0 0 0 0 0 0 1 0 2 (6%)
Hypomagnesemia
 Grade 2 0 0 0 0 0 0 0 2 2 (6%)
 Grade 3–4 0 0 0 0 1 0 0 3 4 (11%)
Nausea/vomiting
 Grade 2 0 0 0 0 0 0 0 1 1 (3%)
Mucositis
 Grade 2 0 0 0 0 0 0 0 1 1 (3%)
Anorexia
 Grade 2 0 0 0 0 0 0 0 2 2 (6%)
Hypertension
 Grade 2 0 0 0 0 0 0 0 1 1 (3%)
Bleeding
 Grade 3 0 0 0 0 1 0 0 2 3 (8%)
Elevated AST/ALT
 Grade 3 0 0 0 0 0 0 0 1 1 (3%)
Anemia
 Grade 3 0 0 0 0 1 0 0 0 1 (3%)
Transvaginal fistula
 Grade 4 0 0 0 0 2 0 0 0 2 (6%)

* Cetuximab dose shown as loading dose and maintenance dose